Skip to Content
Merck
CN
  • Pepsin concentrations are elevated in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis after lung transplantation.

Pepsin concentrations are elevated in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis after lung transplantation.

The Journal of surgical research (2013-07-13)
Christopher S Davis, Bernardino M Mendez, Diana V Flint, Karen Pelletiere, Erin Lowery, Luis Ramirez, Robert B Love, Elizabeth J Kovacs, P Marco Fisichella
ABSTRACT

Aspiration of gastroesophageal refluxate has been implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF) and the progression of bronchiolitis obliterans syndrome after lung transplantation. The goals of the present study were to identify lung transplant patients at the greatest risk of aspiration and to investigate the causative factors. From September 2009 to November 2011, 252 bronchoalveolar lavage fluid (BALF) samples were collected from 100 lung transplant patients. The BALF pepsin concentrations and the results of transbronchial biopsy, esophageal function testing, barium swallow, and gastric emptying scan were compared among those with the most common end-stage lung diseases requiring lung transplantation: IPF, chronic obstructive pulmonary disease, cystic fibrosis, and α1-antitrypsin deficiency. Patients with IPF had higher BALF pepsin concentrations and a greater frequency of acute rejection than those with α1-antitrypsin deficiency, cystic fibrosis, or chronic obstructive pulmonary disease (P = 0.037). Moreover, the BALF pepsin concentrations correlated negatively with a lower esophageal sphincter pressure and distal esophageal amplitude; negatively with distal esophageal amplitude and positively with total esophageal acid time, longest reflux episode, and DeMeester score in those with chronic obstructive pulmonary disease; and negatively with the upright acid clearance time in those with IPF. Our results suggest that patients with IPF after lung transplantation are at increased risk of aspiration and a greater frequency of acute rejection episodes, and that the risk factors for aspiration might be different among those with the most common end-stage lung diseases who have undergone lung transplantation. These results support the role of evaluating the BALF for markers of aspiration in assessing lung transplant patients as candidates for antireflux surgery.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Pepsin from porcine gastric mucosa, Suitable for manufacturing of diagnostic kits and reagents, lyophilized powder, ≥3200 units/mg protein
Sigma-Aldrich
Pepsin from porcine gastric mucosa, powder, ≥250 units/mg solid
Sigma-Aldrich
Pepsin from porcine gastric mucosa, powder, ≥400 units/mg protein
Sigma-Aldrich
Pepsin from porcine gastric mucosa, powder, slightly beige, ≥500 U/mg
Sigma-Aldrich
Pepsin from porcine gastric mucosa, lyophilized powder, ≥3,200 units/mg protein
Sigma-Aldrich
Pepsin from porcine gastric mucosa, powder, slightly beige, 1200-2400 U/mg
Sigma-Aldrich
Pepsin from porcine gastric mucosa, tested according to Ph. Eur.
Sigma-Aldrich
Pepsin from porcine gastric mucosa, Vetec, reagent grade
Sigma-Aldrich
Pepsin−Agarose from porcine gastric mucosa, lyophilized powder, ≥30 units/mg dry solid